首页> 外文OA文献 >Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

【2h】

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

机译：多中心II期临床试验报告：不可切除的胆道癌患者每两周一次贝伐单抗和每日厄洛替尼联合治疗：II期联合体研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lubner, Sam J.; Mahoney, Michelle R.; Kolesar, Jill L.; LoConte, Noelle K.; Kim, George P.; Pitot, Henry C.; Philip, Philip A.; Picus, Joel; Yong, Wei-Peng; Horvath, Lisa; Van Hazel, Guy; Erlichman, Charles E.; Holen, Kyle D.;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. [J] . Lubner SJ, Mahoney MR, Kolesar JL, Journal of Clinical Oncology . 2010,第21期

机译：一项多中心的II期临床试验报告：对不可切除的胆道癌患者每两周一次贝伐单抗和厄洛替尼联合治疗：
2. PP63 Predictive markers in patients with upper gastrointestinal (GI) cancers treated with erlotinib and bevacizumab in a multicenter phase II trial [J] . K.S.Rohrberg, I.Buysschaert, H.Pappot, European Journal of Cancer Supplements . 2009,第4期

机译：在一项多中心II期临床试验中，厄洛替尼和贝伐单抗治疗的上消化道（GI）癌症患者的PP63预测标志物
3. 6506 Predictive markers in patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab in a multicenter phase II trial [J] . K.Rohrberg, H.Pappot, B.G.Skov, European Journal of Cancer Supplements . 2009,第2期

机译：在一项多中心II期临床试验中，厄洛替尼和贝伐单抗治疗的上消化道癌患者的6506个预测指标
4. Clinical studies of SP1049C, a polymer based anthracycline effective against drug resistant tumors. Results of phase II trial and pivotal phase Ⅲ program in upper gastrointestinal cancer indications [C] . Valery Alakhov Controlled Release Society Annual Meeting and Exposition . 2007

机译：SP1049C的临床研究，一种基于聚合物的蒽环类药物可有效抵抗耐药性肿瘤。上消化道癌适应症的II期试验和关键性III期试验结果
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study [O] . Sam J. Lubner, Michelle R. Mahoney, Jill L. Kolesar, -1

机译：多中心II期临床试验报告：不可切除的胆道癌患者每两周一次贝伐单抗和每日厄洛替尼联合治疗：II期联合体研究
7. Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress [O] . T. Kato, H. Satake, K. Oba, 2018

机译：双周IB / II对双周TAS-102的研究与贝伐单抗组合患者转移结直肠癌难以标准疗法（比特研究） - 正在进行中的试验

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

著录项

引文网络

相似文献

相关主题

期刊订阅